PNN DigitalPNN Digital
    Facebook Twitter Instagram
    Sunday, June 1
    Trending
    • Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%
    • Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr
    • IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25
    • Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers
    • WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law
    • Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth
    • Profin Range of Aluminium Profiles by Hafele
    • Business Outline Announces the Business Elite Award | Recognising Exceptional Business Leaders and Companies
    Submit News
    Twitter LinkedIn Instagram
    PNN DigitalPNN Digital
    Subscribe
    • Home
    • News
    • Business
    • Entertainment
    • National
    • Lifestyle
    • More
      • Sports
      • Health
      • Finance
      • Education
    PNN DigitalPNN Digital
    Home»Health

    Eyestem files for IND approval for its product to treat geographic atrophy, the largest cause of incurable blindness in the world for people over 50

    PNN DigitalPNN Digital Health 2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Bengaluru (Karnataka) [India], June 5: Dry age-related macular degeneration (dry AMD) is the largest cause of incurable blindness in the world for patients over 50 years. 170 million people suffer from this disease around the world, 25 million of which are in India. These numbers will, unfortunately, increase in the coming decades as our population ages. The more severe version of dry AMD is geographic atrophy, and no therapy is available to arrest or reverse this loss of vision.

    Eyestem Research today announced the submission of an Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) to begin first-in-human trials of Eyecyte-RPE™for subjects with medium- and late-stage geographic atrophy, secondary to dry AMD.

    Dr. Rajani Battu, Chief Medical Officer of Eyestem Research, said, “We are excited to start human trials for Eyecyte-RPE™. Dry AMD is a huge disease burden, and this therapy has the potential to make a meaningful difference in our patient’s lives.”

    Dr. Jogin Desai, Chief Executive Officer of Eyestem Research, said, “Most cell and gene therapy products under development in the West are estimated to cost over US$ 200,000.Our vision is to democratize access to such treatments at a fraction of these costs and begin disruption of the current status quo with our Eyecyte-RPE™ product.”

    Eyestem Research is a deep science company incubated at the Centre for Cellular and Molecular Platforms, Bangalore, and supported by DBT-BIRAC as well as prestigious Indian and global healthcare investors. The IND submission for Eyecyte-RPE™is supported by robust GLP toxicology data from Dabur Research Foundation in India and excellent efficacy/safety data in animal models at Oregon Health and Science University. Validation of the injection technique and dose-finding studies were done in advanced animal models at the Singapore Eye Research Institute.

    About Eyecyte-RPE™

    Eyecyte-RPE™ is a patented suspension of iPSC-derived fate-committed retinal pigment epithelium cells, which are highly potent, safe, and efficacious in in-vitro and in-vivo studies. The cells are derived from induced pluripotent stem cells, are allogeneic in nature, and can be stored for long periods of time.

    If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    PNN Digital
    • Website

    Keep Reading

    Apollo Hospitals Hyderguda: Advancing Neighbourhood Healthcare with Comprehensive Services

    Brother’s Gift of Life: Shalby Hospital Surat Performs Successful Kidney Transplant

    A New Era in Non-Surgical Facelifts: Sakhiya Skin Clinic Champions the Rise of Thread Lifting

    Swasth Hriday Ignites Digital Transformation Dialogue at HEALTHTECH 2025 in Vapi

    Vedanta Aluminium Organises Mega Health Camp for Rural Communities in Sundargarh

    How Bangalore Is Fighting Substance Abuse Through Rehabilitation

    Recent Posts
    • Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%
    • Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr
    • IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25
    • Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers
    • WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law

    Aayush Wellness’s FY25 Revenue Rockets 8,645%, Net Profit Soars 489%

    31/05/2025

    Aristo Bio-Tech FY25 PAT Rises to Rs 4.06 Cr, Revenue Jumps 30 Percent to Rs 318.09 Cr

    31/05/2025

    IFL Enterprises Ltd reports stellar turnaround in FY25; PAT up 348 Percent Y-o-Y to Rs. 3.04 crore in Q4FY25

    31/05/2025

    Deliure Unveils Exclusive Tres Leches Cakes for Mumbai’s Dessert Lovers

    30/05/2025

    WARF Invites Colleges to Join India’s Top 2025 Ranking Survey for Engineering, Medical, MBA and Law

    30/05/2025

    Maximus International’s Momentum Continues: Strategic Investments Fuel 26 Percent EBITDA Growth

    30/05/2025
    Facebook Twitter Pinterest Vimeo WhatsApp TikTok Instagram

    MENU

    • Home
    • Business
    • Education
    • Home
    • Business
    • Education
    • National
    • Lifestyle

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2025 PNN Digital. Designed by Primex Media Services.
    • About Us
    • Legal Disclaimer
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.